Inozyme Pharma Inc Cash Flow Conversion Efficiency
Inozyme Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Inozyme Pharma Inc (INZY) has a cash flow conversion efficiency ratio of -0.917x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.15 Million) by net assets ($31.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inozyme Pharma Inc (2018–2024)
Cash flow conversion efficiency of Inozyme Pharma Inc from 2018 to 2024. This chart illustrates how Inozyme Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INZY live share price for real-time trading data and today's change.
Inozyme Pharma Inc Cash Flow Conversion Ratio Explained
Inozyme Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inozyme Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inozyme Pharma Inc ranked by their cash flow conversion efficiency. Also see Inozyme Pharma Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Ochrony Środowiska SA
WAR:BOS
|
0.047x |
|
FSP Technology Inc
TW:3015
|
-0.011x |
|
Patel Engineering Limited
NSE:PATELENG
|
0.086x |
|
Austindo Nusantara Jaya Tbk
JK:ANJT
|
-0.022x |
|
Rishabh Instruments Limited
NSE:RISHABH
|
0.045x |
|
Kyobo With Special Purpose Acq
KQ:205100
|
0.044x |
|
Sonda S.A
SN:SONDA
|
0.054x |
|
Amorepacific Corp Pref
KO:090435
|
0.030x |
Annual Cash Flow Conversion Efficiency for Inozyme Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Inozyme Pharma Inc from 2018 to 2024. Review INZY financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.83 Million | $-91.91 Million | -1.589x | -215.92% |
| 2023-12-31 | $140.48 Million | $-70.67 Million | -0.503x | -3.12% |
| 2022-12-31 | $118.39 Million | $-57.76 Million | -0.488x | -10.71% |
| 2021-12-31 | $109.27 Million | $-48.15 Million | -0.441x | -93.68% |
| 2020-12-31 | $158.10 Million | $-35.97 Million | -0.228x | -140.18% |
| 2019-12-31 | $-33.22 Million | $-18.81 Million | 0.566x | -16.75% |
| 2018-12-31 | $-13.88 Million | $-9.44 Million | 0.680x | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more